Media Articles Related to Intuniv (Guanfacine)
Shire receives European approval for INTUNIV as a non-stimulant ADHD treatment for children and adolescents
Source: ADHD / ADD News From Medical News Today [2015.09.21]
Shire has announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant INTUNIV® (guanfacine hydrochloride prolonged release tablets) for the treatment of...
Targeted Therapies May Ease Severe Pulmonary Hypertension
Source: Medscape Critical Care Headlines [2015.09.29]
A new analysis has spotted a mortality reduction in patients with severe pulmonary hypertension caused by lung disease, but doubts remain.
Medscape Medical News
Targeting hypertension by helping pharmacists deliver enhanced patient care
Source: Hypertension News From Medical News Today [2015.09.21]
Patients with high blood pressure are benefiting from the expanded role played by pharmacists in Alberta, according to a new study from the University of Alberta's Faculty of Medicine & Dentistry.
Hypertension drug reduces inflammation from traumatic brain injury
Source: Hypertension News From Medical News Today [2015.09.21]
A new study on the processes causing inflammation after a TBI identifies a protein produced in the liver that can be blocked using a drug for hypertension.
New imaging technique reveals early brain damage caused by hypertension
Source: Hypertension News From Medical News Today [2015.09.18]
Researchers have found that a new imaging technique known as diffusion tensor imaging can show when high blood pressure causes early damage to neural pathways in the brain.
Published Studies Related to Intuniv (Guanfacine)
Efficacy of guanfacine extended release assessed during the morning, afternoon,
and evening using a modified Conners' Parent Rating Scale-revised: Short Form. 
attention-deficit/hyperactivity disorder (ADHD)... CONCLUSIONS: These results provide further support for the demonstrated efficacy
Randomized, double-blind trial of guanfacine extended release in children with
attention-deficit/hyperactivity disorder: morning or evening administration. 
CONCLUSIONS: GXR administered either in the morning or evening was associated
Naltrexone with or without guanfacine for preventing relapse to opiate addiction
in St.-Petersburg, Russia. 
induced craving and have reduced opiate relapse in small clinical trials... CONCLUSIONS: Adding guanfacine to naltrexone did not improve treatment retention
Guanfacine extended-release: in attention deficit hyperactivity disorder. [2010.09.10]
Guanfacine, an alpha(2A)-adrenoceptor agonist, is available in the US as an extended-release (ER) tablet for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents (aged 6-17 years). In two large, randomized, double-blind, placebo-controlled trials of 8 and 9 weeks' duration, guanfacine ER (1-4 mg once daily) was effective in reducing the symptoms of ADHD (hyperactivity, impulsivity and inattention) in children and adolescents...
Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. [2010.09.01]
CONCLUSIONS: In this population of children aged 6-12 years with ADHD and the presence of oppositional symptoms, significant reductions in CPRS-R:L oppositional subscale and ADHD-RS-IV total scores were observed with guanfacine XR treatment compared with placebo. Treatment with guanfacine XR at optimized doses was associated with mostly mild or moderate TEAEs. The findings of this study support the efficacy of guanfacine XR in the treatment of children with ADHD and the presence of oppositional symptoms. Clinical Trial Registration Number: NCT00367835.
Clinical Trials Related to Intuniv (Guanfacine)
Efficacy of Intuniv Extended Release as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD [Recruiting]
This study looks to examine whether or not INTUNIV extended release can help children aged
6-12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) in improving
Executive Function when added to their usual care stimulant therapy. Executive functions
are a set of mental processes that include emotional control, planning, organization,
working memory, inhibition of behaviors, and managing time and space. As children with ADHD
usually have difficulties with Executive Function, and Executive function difficulties lead
to more difficulties in school and behaviour, it is anticipated that adding INTUNIV extended
release to usual stimulant therapy will improve Executive Function scores as rated by
parents and teachers. Improvements in quality of life will also be measured.
PK/PD Comparison of Guanfacine ER and IR [Active, not recruiting]
Evaluate whether a 4mg/day or 6/mg day dose of extended-release guanfacine produces
pharmacokinetic/dynamic (PK/PD) properties similar to 3mg/day immediate release guanfacine.
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder [Recruiting]
Children with explosive aggression are often rejected by their peers, placed in special
classroom, and contribute to family discord. When psychotherapy and family therapy is
unsuccessful, medications are often used. Current medications are stimulants (e. g.
methylphenidate, dextroamphetamine), anticonvulsants (e. g. Divalproex) and antipsychotics
(olanzapine, risperidone). At this time, the available medications are of limited
usefulness, either because they do not always work or because they have side effects such as
weight gain or insomnia. There is a clear need for new medications to treat explosive
aggression when psychotherapy is unsuccessful.
The hypothesis of this study is the medication Intuniv when combined with psychotherapy will
be more helpful to children with explosive aggression than placebo combined with
psychotherapy. Intuniv is a long acting form of guanfacine, a medication approved by the FDA
for treatment of Attention Deficit Hyperactivity Disorder. Intuniv is not a stimulant, nor
is it an anticonvulsant, nor is it an antipsychotic.
The children in this study will be between the ages of 6 and 12 and meet Diagnostic and
Statistical Manual of Psychiatry Fourth Edition, Text Revision (DSM-IV-TR) criteria for
Intermittent Explosive Disorder.
Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65). [Completed]
This is considered an investigator-initiated clinical research trial, which means that your
study doctor is researching a particular medication (in this case a medication that is
currently FDA- approved) for the treatment of AD/HD in individuals ages 6-17. The medication
is guanfacine hydrochloride.
The hypothesis is that this medication could be used in adults with Attention
Deficit/Hyperactivity Disorder who have not received satisfactory results with their current
stimulant ADHD medication. The study drug is investigational for use in adults.
Investigational means it has not been approved by the U. S. Food and Drug Administration
(FDA) for use in adults.
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder [Completed]
The purpose of this study is to determine whether guanfacine (trade name Intuniv) by itself
or in combination with methylphenidate (also known as Ritalin) is helpful for treating
hyperactivity in children and adolescents with a Pervasive Developmental Disorders (PDDs).
Reports of Suspected Intuniv (Guanfacine) Side Effects
OFF Label USE (7),
Loss of Consciousness (6),
Inappropriate Schedule of Drug Administration (6),
Convulsion (6), more >>